James V. Caggiano
Directeur Général chez Dendreon Pharmaceuticals, Inc.
Profil
James V.
Caggiano is currently the Chief Executive Officer at Targazyme, Inc., and Evolve Biologics, Inc. He was also the Chief Executive Officer at Dendreon Pharmaceuticals, Inc. in the past.
Prior to that, he held the position of Vice President-Sales & Marketing at Dendreon Corp.
Mr. Caggiano completed his undergraduate degree at Cornell University and earned an MBA from Kellogg School of Management.
Postes actifs de James V. Caggiano
| Sociétés | Poste | Début |
|---|---|---|
Dendreon Pharmaceuticals, Inc.
 Dendreon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Dendreon Pharmaceuticals, Inc. discovers, develops and commercializes novel products for the treatment of cancer. The company is headquartered in Olympia, WA. | Directeur Général | - |
Targazyme, Inc.
 Targazyme, Inc. BiotechnologyHealth Technology Targazyme, Inc. operates as a biotechnology company. It develops and commercializes breakthrough products. The firm offers products for stem cell transplantation, immunotherapy for cancer, regenerative medicine, and gene therapy. The company was founded by Lynnet Koh and is headquartered in Carlsbad, CA. | Directeur Général | 11/09/2020 |
Evolve Biologics, Inc.
 Evolve Biologics, Inc. Pharmaceuticals: MajorHealth Technology Evolve Biologics, Inc. is a Canadian plasma-derived therapeutics company headquartered in Mississauga, CA. The company is focused on commercializing a portfolio of product candidates, including intravenous immunoglobulin (IVIG) and human serum albumin (HSA), both of which are in advanced stages of regulatory approval with the FDA and Health Canada. Evolve's state-of-the-art facility is the first to use its innovative and proprietary technology, Plasmacap EBA®, to commercially produce plasma-derived therapeutics. The company has recently appointed James V. Caggiano as CEO, who brings nearly 30 years of experience in the biotech, pharma, and medical device industries. | Directeur Général | 19/01/2021 |
Anciens postes connus de James V. Caggiano
| Sociétés | Poste | Fin |
|---|---|---|
| DENDREON CORPORATION | Sales & Marketing | - |
Formation de James V. Caggiano
| Cornell University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Targazyme, Inc.
Targazyme, Inc. BiotechnologyHealth Technology Targazyme, Inc. operates as a biotechnology company. It develops and commercializes breakthrough products. The firm offers products for stem cell transplantation, immunotherapy for cancer, regenerative medicine, and gene therapy. The company was founded by Lynnet Koh and is headquartered in Carlsbad, CA. | Health Technology |
Dendreon Pharmaceuticals, Inc.
Dendreon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Dendreon Pharmaceuticals, Inc. discovers, develops and commercializes novel products for the treatment of cancer. The company is headquartered in Olympia, WA. | Health Technology |
Evolve Biologics, Inc.
Evolve Biologics, Inc. Pharmaceuticals: MajorHealth Technology Evolve Biologics, Inc. is a Canadian plasma-derived therapeutics company headquartered in Mississauga, CA. The company is focused on commercializing a portfolio of product candidates, including intravenous immunoglobulin (IVIG) and human serum albumin (HSA), both of which are in advanced stages of regulatory approval with the FDA and Health Canada. Evolve's state-of-the-art facility is the first to use its innovative and proprietary technology, Plasmacap EBA®, to commercially produce plasma-derived therapeutics. The company has recently appointed James V. Caggiano as CEO, who brings nearly 30 years of experience in the biotech, pharma, and medical device industries. | Health Technology |